CD276 and glioblastoma: Namely, the specific expression of 4IgB7-H3 in glioblastoma cells and higher expression of 2IgB7-H3 in recurrent glioblastoma and its correlation to temozolomide resistance indicate that B7-H3 can be explored as a therapeutic target, but also as a biomarker of tumor recurrence.